F. Kiertsman

Latex allergy in dentistry: clinical cases report

F. Mendes, D. Raggio, G. Politano, 2010 .

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

P. Fenaux, Y. Miyazaki, U. Platzbecker, 2019, Blood.

RestosepiteliaisdeMalasseznoligamentoperiodontalesuapossível relaçãocomanquilosedento-alveolar* Epithelial rests of Malassez in periodontal ligament and possible association with ankylosis

D. Raggio, A. Chelotti, L. B. Camargo, 2008 .

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

P. Postmus, Keunchil Park, R. Dziadziuszko, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

P. Fenaux, Y. Kwong, K. Ando, 2022, Blood.

The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

J. Esteve, P. Fenaux, M. Sekeres, 2020 .

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.

R. Cairoli, V. Santini, A. Zeidan, 2023, The Lancet. Haematology.